Navigation Links
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Date:5/10/2013

NEW YORK, May 10, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a securities class action has been commenced in the United States District Court for the District of Massachusetts on behalf of a class (the "Class") of purchasers of Aveo Pharmaceutical, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) securities between January 3, 2012 and May 1, 2013 (the "Class Period").

Aveo is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapies.  The Company's lead product is an oral inhibitor of the vascular endothelial growth factor ("VEGF") receptors.

The Complaint alleges that throughout the Class Period, Defendants conditioned investors to believe that the Company's drug Tivopath (or Tivozanib) would receive approval from the U.S. Food and Drug Administration ("FDA") through a host of materially false and misleading statements regarding its Phase III ("TIVO-1") trial design and results.  Specifically, the Company (a) failed to disclose to investors that the FDA had recommended that the Company conduct an additional Phase III trial due to adverse trends in the Company's first study; (b) misled investors regarding the overall safety and efficacy of the product, including failing to disclose the 25% higher rate of death associated with Tivozanib therapy compared to the control drug, Sorafenib; and (c) failed to disclose that almost 90% of the patients studied in TIVO-1 were enrolled from sites in Central and Eastern Europe with inconsistent treatment patterns from those in the U.S.  As a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

On April 30, 2013, the FDA released its Oncologic Drugs Advisory Committee ("ODAC")
'/>"/>

SOURCE Bernstein Liebhard LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
2. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
3. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner to organizations ... May 14-16, 2014 at the Global Center for Health ... This is the premier industry event for ... open innovation. Participants will learn how world-changing innovation is ...
(Date:1/14/2014)... , January 14, 2014 Equashield ... for hazardous drugs, today announced that it has ... straight year.   Equashield,s closed systems ... pharmacists, nurses and other medical professionals who prepare ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... NEW YORK, Jan. 11, 2011 Reportlinker.com announces ... in its catalogue: Innovative Drug ... http://www.reportlinker.com/p0359990/Innovative-Drug-Discovery-in-Emerging-Markets.html Introduction Emerging markets ... pharmaceutical industry, but it has been unclear the ...
... (Nasdaq: STXS ) announces the first successful ... as the company received CE Mark for this latest ... with the Vdrive system, Tamas Szili-Torok, MD, Ph.D., from ... Center in The Netherlands, successfully treated atrial fibrillation in ...
Cached Medicine Technology:Reportlinker Adds Innovative Drug Discovery in Emerging Markets 2Reportlinker Adds Innovative Drug Discovery in Emerging Markets 3Stereotaxis Announces CE Mark and First Human Case for Vdrive™ 2Stereotaxis Announces CE Mark and First Human Case for Vdrive™ 3
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... In 2009 the influenza pH1N1 virus caused the first ... Finland in May 2009 and killed more than 50 ... infects Finns mainly during flu epidemics (winter/spring seasons). ... to serious complicated illnesses. World Health Organization has recommended ... illness. The disadvantage of this drug is that it ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... testosterone falls below normal levels are more likely to ... heart disease and type 2 diabetes. A new simple ... testing and possible treatment is described in an article ... publication from Mary Ann Liebert, Inc., publishers. The article ... Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... help because of illnesses related to alcohol abuse seem to ... ,Current official statistics show that emergency wards in ... and emergencies caused due to drunkenness since 1997. ... also have doubled, reported NHS since 1997, accounting for more ...
... up for pricey wine appreciation classes to parse the subtle ... and the black currant// scent of a cabernet sauvignon. Just ... quickly help you become a modest oenophile. It’s up to ... ,A new study by Northwestern University researchers shows that the ...
... official journal of the American Neurological Association, examined brain ... devastated in FTD//. ,Von Economo neurons (VENs) ... evolved in a select group of socially complex species: ... Across species, VENs are localized to frontal brain regions ...
... reach for aspirin. What is giving researchers a headache ... whether there is another form on top of the long-known ... India seems to have solved this controversial puzzle: yes, there ... pure form. ,“The two crystalline forms of ...
... the risk to develop stroke than men, discovered a British study ... of blood to the brain or due to tiny blockages in ... who suffered strokes had 40% more chance to have a family ... chances in those women having mothers who also had a history ...
... finds that 95 percent of Americans have pre marital sex-sex ... American men //and women as far back as the 1940 ... spending hundreds of millions of dollars advising young adults to ... One official disagreed and opined that even if the programs ...
Cached Medicine News:Health News:Researchers Discover How We Differentiate Smells 2Health News:A Study Finds VENs Devastated in FTD 2Health News:Does Aspirin Crystallize? 2
... is a premium agarose used for isolating ... agarose produces clear sharp bands, with no ... of UltraClean Forensic Agarose is tested and ... RNase activity and DNA contamination. ...
... is specifically formulated for high resolution of ... bp. This standard melting temperature agarose can ... 10 bp difference in size. UltraPure™ ... structure for better handling and improved clarity ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... solid. Highly purified non-ionic fraction of agar. ... very low concentrations. Can be mounted on ... films are elastic and durable and show ... either protein or lipoprotein dyes. Contaminants: ...
Medicine Products: